Blog
Discover our latest articles and blogs
Patients: Why A CYP2D6 Poor Metabolizer Can Make Codeine Ineffective
Learn how a CYP2D6 poor metabolizer affects drugs like codeine, why other medicines can mimic poor metabolism, and how living PGx reports keep guidance...
Profile First, Example Driven FHIR Genomics DocumentReference for Labs
Profile first reference for labs: annotated FHIR DocumentReference JSON, checklist, file access tips and integration notes.
Labs and Clinicians: 62% Concordance in CYP2D6 Inhibitor Labels
Clinicians and labs: practical CYP2D6 inhibitor guidance. Explains the 62% FDA concordance gap, phenoconversion phenotype adjustment, and reporting steps.
Avoid Clopidogrel in CYP2C19 Poor Metabolizers: Clinician Actions
Why two no function CYP2C19 alleles reduce clopidogrel effectiveness, when to test, how to switch therapy, and practical lab reporting options for...
7 FHIR Ready PGx Report Sections for Labs and Clinicians
Standards first checklist for labs and clinicians to build FHIR ready PGx reports with genotype to phenotype translation, phenoconversion checks,...
Labs: Ship CLIA Ready AI in PGx Reporting in Four Phases
A lab executive playbook to deploy AI in PGx with CLIA grade validation, HL7/FHIR EHR integration, and a four phase pilot to prevent audit surprises.
6 GDPR DPIA Questions DPOs Must Answer for Genetic Data
A DPO playbook for GDPR DPIAs on genetic data: six screening questions, practical mitigations tied to Articles 35 and 9, plus lab-ready options.
Ready in 5 days: UGT1A1 Reporting for Irinotecan Labs
A lab-to-clinician playbook for irinotecan UGT1A1 reporting: reconciled DPWG/FDA/CERSI-PGx dosing, copy ready interpretive text, SNOMED coding, and 5 day...
3 Essential Prerequisites for Direct Secure Messaging in PGx Labs
A practical lab checklist for delivering PGx reports via Direct: the three prerequisites, 1-hour MDN SLA, HL7/FHIR payload patterns, and phased rollout steps.